Organization
US Oncology Research and Rocky Mountain Cancer Centers
1 abstract
Abstract
A first-in-human study of the potent and highly selective BTK degrader ABBV-101 in patients with relapsed/refractory B-cell malignancies.Org: Willamette Valley Cancer Institute and Reserach Center, US Oncology Hematology Research Program, US Oncology Research and Rocky Mountain Cancer Centers,